Drug Profile


Alternative Names: AKCEA-APOCIII-LRx; GalNAc3 conjugated antisense oligonucleotide - Ionis Pharmaceuticals; IONIS-APOCIII-LRx; ISIS-APOCIII-LRx

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Akcea Therapeutics; Ionis Pharmaceuticals
  • Class Antihyperlipidaemics; Antisense oligonucleotides
  • Mechanism of Action Apolipoprotein C-III inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hypertriglyceridaemia

Most Recent Events

  • 06 Jan 2017 Ionis Pharmaceuticals, Akcea Therapeutics and Novartis enter into an optional licensing agreement to co-promote and co-develop AKCEA-APOCIII-LRx for Hyperlipoproteinaemia
  • 06 Jan 2017 Ionis Pharmaceuticals and Akcea Therapeutics plans a phase II trial for Hypertriglyceridaemia
  • 01 Sep 2016 Phase-I clinical trials in Hypertriglyceridaemia (In volunteers) in Canada (SC) (NCT02900027)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top